NUCRYST to Present at Rodman & Renshaw 10th Annual healthcare Conference on November 10, 2008

    WAKEFIELD, MA, Oct. 21 /CNW/ - NUCRYST Pharmaceuticals, a developer and
manufacturer of medical products that fight infection and inflammation, today
announced that executive management will participate in the Rodman & Renshaw
Annual Global Investment Conference to be held November 10 through November
12, 2008 at the New York Palace Hotel in New York, NY. Thomas E. Gardner,
Chairman and Chief Executive Officer, is scheduled to present an overview of
the company and its development programs at 12:25 p.m. EDT on Monday, November
10, 2008.
    To listen to the audio web cast of the presentation during or after the
event, please visit: An archive of the presentation will be
available for replay for 90 days.

    About NUCRYST Pharmaceuticals

    NUCRYST Pharmaceuticals (NASDAQ:   NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using SILCRYST(TM), its patented atomically disordered nanocrystalline silver
technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care
coating products to Smith & Nephew plc, which markets these products in over
30 countries under their Acticoat(TM) trademark. NUCRYST is also developing
pharmaceutical products to address medical conditions that are characterized
by pain, infection and inflammation. The Company has developed its proprietary
nanocrystalline silver in a powder form, referred to as NPI 32101 for use in
medical devices and as an active pharmaceutical ingredient.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

    Statements made at the upcoming conferences may contain forward-looking
statements within the meaning of securities legislation in the United States
and Canada (collectively "forward-looking statements"). Such forward-looking
statements involve risks and uncertainties that could cause actual results to
differ from predicted results. Forward-looking factors that may be discussed
include, but are not limited to the performance of stock markets generally;
our ability to satisfy regulatory and stock exchange standards and
requirements to maintain our exchange listing; our future operation results
are uncertain and likely to fluctuate; our ability to maintain our
collaboration with Smith & Nephew; our reliance on sales of Acticoat(TM)
products with our SILCRYST(TM) coatings by Smith & Nephew; future financial
performance and operating performance of Smith & Nephew; we may not be able to
retain existing and obtain new regulatory approvals for any future products;
continued development and market acceptance of new products; the impact of
competitive products and pricing; we may not be able to establish successful
commercialization programs, through new corporate collaborations or otherwise;
changes in currency exchange rates; our ability to protect our intellectual
property rights and to not infringe on the intellectual property rights of
others. For a more thorough discussion of the risks associated with our
business, see the "Risk Factors" section in our Annual Report on Form 10-K for
the year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2008, filed with the U.S. Securities and Exchange
Commission on EDGAR at and with securities authorities in Canada
on SEDAR at

    %SEDAR: 00023031E

For further information:

For further information: David B. Holtz, Vice President and Chief
Financial Officer, NUCRYST Pharmaceuticals, (781) 224-1444,;
Fern Lazar, Lazar Partners, (212) 867-1762

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890